Fresenius SE KGaA (BRSE:000332902) - Stock Price, News & Analysis

000332902 Stock Overview

A health care company, provides products and services for chronically ill patients. More details

000332902 fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	3/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Rewards

Trading at 63.8% below our estimate of its fair value

Earnings are forecast to grow 39.03% per year

Risk Analysis

Shares are highly illiquid

Has a high level of debt

Fresenius SE & Co. KGaA Competitors

Straumann Holding

SWX:STMN

CHF 17.6b

Sonova Holding

SWX:SOON

CHF 18.9b

Galenica

SWX:GALE

CHF 3.8b

Alcon

SWX:ALC

CHF 37.8b

Price History & Performance

Summary of all time highs, changes and price drops for Fresenius SE KGaA
Historical stock prices
Current Share Price	€53.06
52 Week High	€0
52 Week Low	€0
Beta	1.04
11 Month Change	0%
3 Month Change	0%
1 Year Change	0%
33 Year Change	0%
5 Year Change	0.019%
Change since IPO	7.82%

Recent updates

Shareholder Returns

	000332902	CH Healthcare	CH Market
7D	0%	-1.2%	-2.2%
1Y	0%	7.3%	6.2%

Return vs Industry: 000332902 underperformed the Swiss Healthcare industry which returned 8.1% over the past year.

Return vs Market: 000332902 underperformed the Swiss Market which returned 6.1% over the past year.

Price Volatility

Is 000332902's price volatile compared to industry and market?
000332902 volatility
000332902 Average Weekly Movement	n/a
Healthcare Industry Average Movement	4.1%
Market Average Movement	3.3%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	1.6%

Stable Share Price: 000332902's share price has been volatile over the past 3 months compared to the Swiss market.

Volatility Over Time: Insufficient data to determine 000332902's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1912	177,091	Michael Sen	www.fresenius.com

Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Fresenius SE & Co. KGaA Fundamentals Summary

How do Fresenius SE KGaA's earnings and revenue compare to its market cap?
000332902 fundamental statistics
Market cap	CHF 17.57b
Earnings (TTM)	-CHF 447.93m
Revenue (TTM)	CHF 21.33b

0.8x

P/S Ratio

-39.2x

P/E Ratio

Is 000332902 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
000332902 income statement (TTM)
Revenue	€22.81b
Cost of Revenue	€17.48b
Gross Profit	€5.33b
Other Expenses	€5.81b
Earnings	-€479.00m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.85
Gross Margin	23.37%
Net Profit Margin	-2.10%
Debt/Equity Ratio	60.9%

How did 000332902 perform over the long term?

See historical performance and comparison

000332902 Stock Overview

Rewards

Risk Analysis

Fresenius SE & Co. KGaA Competitors

SWX:STMN

CHF 17.6b

SWX:SOON

CHF 18.9b

SWX:GALE

CHF 3.8b

SWX:ALC

CHF 37.8b

Price History & Performance

Recent News & Updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

Recent updates

PAI Mid-Market Fund SCSp. managed by PAI Partners completed the acquisition of 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Second quarter 2024 earnings released: EPS: €0.34 (vs €0.21 loss in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.49 (vs €0.61 in 1Q 2023)

PAI Mid-Market Fund SCSp. managed by PAI Partners agreed to acquire 67% stake in Vamed rehabilitation business from Fresenius SE & Co. KGaA (XTRA:FRE).

Verme family with other shareholders completed the acquisition of additional 70% stake in Clinica Ricardo Palma S.A. from Fresenius SE & Co. KGaA (XTRA:FRE).

New major risk - Financial position

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC completed the acquisition of EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE).

German Fresenius Reportedly Seeks to Sell Vamed Reha

Fresenius SE & Co. KGaA to Report Fiscal Year 2023 Final Results on Mar 14, 2024

IVIRMA Global SL and GED Iberian Private Equity, S.A., SGEIC agreed to acquire EUVITRO S.L.U. from Fresenius SE & Co. KGaA (XTRA:FRE) for €500 million.

Third quarter 2023 earnings released: €0.72 loss per share (vs €0.57 profit in 3Q 2022)

Fresenius SE & Co. KGaA to Report Q2, 2024 Results on Jul 31, 2024

KKR in Talks to Buy Eugin from Fresenius

Fresenius Reportedly Plans to Offload Digital Subsidiary Curalie

New major risk - Financial position

Second quarter 2023 earnings released: EPS: €0.14 (vs €0.68 in 2Q 2022)

Fresenius SE & Co. KGaA to Report Q3, 2023 Results on Nov 02, 2023

Fresenius Se & Co. Kgaa Proposes Dividend for 2022

Upcoming dividend of €0.92 per share at 3.3% yield

First quarter 2023 earnings released: EPS: €0.61 (vs €0.74 in 1Q 2022)

Fresenius SE & Co. KGaA to Report Q1, 2023 Results on May 09, 2023

Full year 2022 earnings released: EPS: €2.44 (vs €3.26 in FY 2021)

Fresenius SE & Co. KGaA, Annual General Meeting, May 17, 2023

QIC Reportedly Set to Clinch Healius Day Hospital Unit for $140 Million Plus

Third quarter 2022 earnings released: EPS: €0.57 (vs €0.74 in 3Q 2021)

Brookfield Reportedly Drops Out of Race to Buy Healius

Fresenius SE Announces Chief Financial Officer Changes

Fresenius SE & Co. KGaA Announces Michael Sen as CEO on October 1, 2022 Succeeding Stephan Sturm

Second quarter 2022 earnings released: EPS: €0.68 (vs €0.84 in 2Q 2021)

Healius Reportedly Launches Day Surgery Sale Process

Fresenius Kabi Introduces Generic Iodixanol Contrast Media Agent

Upcoming dividend of €0.92 per share

First quarter 2022 earnings released: EPS: €0.74 (vs €0.78 in 1Q 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Fresenius SE & Co. KGaA Provides Earnings Guidance for the Year 2022

Third quarter 2021 earnings released: EPS €0.74 (vs €0.77 in 3Q 2020)

Second quarter 2021 earnings released: EPS €0.84 (vs €0.74 in 2Q 2020)

Upcoming dividend of €0.88 per share

First quarter 2021 earnings released: EPS €0.78 (vs €0.82 in 1Q 2020)

Full year 2020 earnings released: EPS €3.06 (vs €3.38 in FY 2019)

Fresenius SE & Co. KGaA to Report Q1, 2021 Results on May 07, 2021

Fresenius SE & Co. KGaA, Annual General Meeting, May 21, 2021

Third quarter earnings released

Third-quarter earnings released: Revenue misses expectations

Shareholder Returns

Price Volatility

About the Company

Fresenius SE & Co. KGaA Fundamentals Summary

0.8x

-39.2x

Earnings & Revenue